Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Shahid Beheshti University of Medical Sciences

Overview

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Central Retinal Vein Occlusion

Interventions

BevasizumabDRUG

Intravitreal, 1.25 mg, 3 times, one month apart.

Triamcinolone AcetonideDRUG

Intravitreal, 2 mg, 2 times, two months apart.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Recent onset (less than 3 months) central retinal vein occlusion Exclusion Criteria: * Any previous intervention

Locations (1)

Imam Hossein medical center

Tehran, Tehran Province, Iran

RECRUITING

Outcomes

Primary Outcomes

Visual acuity

Time frame: 6 months

Secondary Outcomes

central macular thickness

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.